MLManli Li

Manli Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Manli Li has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Dandan Dong

    Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, China

    1 shared publication
  • Gang Xiao

    Department of Thoracic Surgery Guangzhou First People's Hospital Guangzhou Medical University Guangzhou China

    1 shared publication
  • Heng Lai

    Department of Nephrology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China

    1 shared publication
  • Hua Gan

    Department of Nephrology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China

    1 shared publication
  • Hua Gan

    Department of Nephrology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

    1 shared publication
  • Hui Zhang

    State Key Laboratory of Flexible Electronics (LoFE) & Institute of Advanced Materials (IAM) School of Flexible Electronics (Future Technologies) Nanjing Tech University (NanjingTech) Nanjing China

    1 shared publication

Latest Publications

  • Open Access

    Novel IncR/IncP6 Hybrid Plasmid pCRE3-KPC Recovered from a Clinical KPC-2-Producing Citrobacter braakii Isolate

    by Dandan Dong, Ziqiang Mi, Dujun Li, Mingming Gao, Nan Jia, Manli Li, Yigang Tong, Xianglilan Zhang, Yuanqi Zhu

    Reports of human-pathogenic C. braakii strains, especially of strains showing resistance to carbapenems, are rare. To the best of our knowledge, our results represent the first detection of carbapenemase gene bla KPC-2 in C. braakii strains. In addition, we have studied detailed genetic characteristics of the novel IncR/IncP6 hybrid plasmid pCRE3-KPC, which was isolated from a clinical multidrug-resistant Citrobacter braakii CRE3 strain. Our results may provide further insight into the horizontal transfer of multidrug resistance genes in bacteria and into the genomic diversity and molecular evolution of plasmids.


  • TLR2 protects cisplatin‐induced acute kidney injury associated with autophagy via PI3K/Akt signaling pathway

    by Qing Shen, Xi Zhang, Qiuying Li, Jing Zhang, Heng Lai, Hua Gan, Xiaogang Du, Manli Li

    Toll‐like receptors (TLRs), which are essential components of the innate immune response, play an important role in acute kidney injury (AKI). Toll‐like receptor 2 (TLR2) is constitutively expressed in tubular epithelial cells of the kidney and participates in cisplatin‐induced AKI. The autophagy is a dynamic catabolic process that maintains intracellular homeostasis, which is involved in the pathogenesis of AKI. Recent studies demonstrate that PI3K/Akt signaling pathway regulates autophagy in response to various stimuli. Therefore, we propose that cisplatin might activate TLR2, which subsequently phosphorylates PI3K/Akt, leading to enhanced autophagy of renal tubular epithelial cells and protecting cisplatin‐induced AKI. We found that TLR2 expression was significantly increased in the kidney after the cisplatin treatment. TLR2‐deficient mice exacerbated renal injury in cisplatin‐induced AKI, with higher serum creatinine and blood urea nitrogen, more severe morphological injury compared with that of wild‐type mice. In vitro, we found that inhibition of TLR2 reduced tubular epithelial cell autophagy after the cisplatin treatment. Mechanistically, TLR2 inhibited autophagy via activating PI3K/Akt signaling pathway in renal tubular epithelial cells after the cisplatin treatment. Take together, these results suggest that TLR2 may protect cisplatin‐induced AKI by activating autophagy via PI3K/Akt signaling pathway.


  • Breakdown of the Gut Barrier in Patients with Multiple Organ Dysfunction Syndrome is Attenuated by Continuous Blood Purification: Effects on Tight Junction Structural Proteins

    by Jian-Bin Zhang, Xiao-Gang Du, Hui Zhang, Man-Li Li, Gang Xiao, Jiang Wu, Hua Gan

    Background: Breakdown of the gut barrier increases intestinal permeability and allows movement of intraluminal contents across the mucosa, which can lead to distant organ injury and multiple organ dysfunction syndrome (MODS). Intestinal permeability is associated with alterations in cellular tight junctions involving the structural proteins occludin and zonula occludens-1 (ZO-1). The aim of this study was to investigate the effect of continuous blood purification (CBP) on gut barrier function in patients with MODS. Method: Serum diamine oxidase (DAO) and endotoxin, epithelial monolayer permeability, and transepithelial electrical resistance (TER) were used as markers for the assessment of gut barrier function in 22 patients with MODS who underwent continuous venovenous hemofiltration (CVVH) for 24 hours. Blood samples were taken from patients at 0, 6, 12, and 24 hours during CVVH therapy. Serum DAO and endotoxin were determined by spectrophotography. Permeability and TER were assessed using Caco-2 cell monolayers. Occludin and ZO-1 protein levels were analyzed by immunoblotting and immunofluorescence staining. And inducible nitric oxide synthase (iNOS) mRNA levels and nitric oxide (NO) production were determined by real-time PCR and spectrophotography, respectively. Result: Gut barrier dysfunction was evident in patients with MODS compared with normal controls. Serum DAO, endotoxin levels, and epithelial permeability were elevated, while TER was decreased in patients with MODS, and this change was more pronounced in nonsurvivors. Breakdown and reorganization of occludin and ZO-1 away from tight junctions was found in all MODS patients. After CBP treatment, APACHE II and MODS scores improved significantly. Serum DAO and endotoxin levels and epithelial permeability also diminished, while TER increased in all patients; CBP significantly attenuated breakdown and reorganization of tight junction proteins, and also attenuated the inflammation-induced increase in iNOS mRNA expression and NO production. Conclusion: Breakdown of gut barrier function is present in patients with MODS and may be correlated with poor outcomes in the disease. CBP can not only improve the general conditions, as measured by the APACHE II score, but also improve gut barrier dysfunction by attenuating the breakdown and reorganization of occludin and ZO-1. This beneficial effect of CBP on gut barrier dysfunction is associated with down-regulation of iNOS.